Project Details
Description
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo- Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)
| Status | Active |
|---|---|
| Effective start/end date | 9/29/23 → 3/31/28 |
Funding
- AEROVATE THERAPEUTICS, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.